Navigation Links
In Pretreated Advanced Renal Cell Carcinoma, Thought Leaders' Opinions and Clinical Data Indicate that Tivopath Has Efficacy and Tolerability Advantages Over Currently Used Therapies
Date:3/26/2013

BURLINGTON, Mass., March 26, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. and European oncologists agree that a therapy's effect on overall survival and disease progression are the attributes that most influences their decisions regarding prescribing in advanced renal cell carcinoma. Clinical data and the opinions of interviewed thought leaders indicate that Aveo Oncology/Astellas Pharma/Kyowa Hakko Kirin's Tivopath has advantages over currently used therapies on disease progression.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

According to the DecisionBase 2013 report entitled A Promising Immunotherapy Is on the Horizon. What Attributes Does It Need to Trump the Angiogenesis and mTOR Inhibitors?, surveyed U.S. oncologists indicate that they would prescribe Tivopath to 30 percent of their pretreated advanced renal cell carcinoma patients. However, owing to its Phase III clinical trial design and delay in reaching the already crowded market behind Pfizer's Inlyta, Decision Resources forecasts that Tivopath will earn a more modest 11 percent patient share in the U.S. pretreated advanced renal cell carcinoma market by 2021.

The report also finds that surveyed oncologists and managed care organization (MCO) pharmacy directors indicate that improved overall survival and progression-free survival are the greatest unmet needs in pretreated advanced renal cell carcinoma. Interviewed thought leaders are optimistic that Bristol-Myers Squibb's nivolumab has the potential to improve overall survival and at least in part address this unmet need.

"The MCO pharmacy directors we surveyed are particularly receptive to new pretreated advanced renal cell carcinoma therapies that offer improvements in median overall survival over currently available therapies," said Decision Resources Analyst Samuel Mentzer . "While some emerging therapies, such as nivolumab, hold promise, we do not expect any will match the clinical improvement over current therapies that surveyed U.S. payers indicated would be necessary for widespread inclusion on MCO formularies."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
2. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
3. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
4. Biomedical Advanced Research and Development Authority (BARDA) Exercises Option with Pfenex Inc. To Extend Contract for the Development of a Recombinant Protective Antigen (rPA) Based Anthrax Vaccine
5. Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients
6. Reduction of Chemotherapy and PET-Guided Radiotherapy in Advanced-Stage Hodgkin Lymphoma: the GHSG HD15 Trial
7. Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinsons Disease
8. PeriGen, Inc. Introduces New, Advanced Perinatal System at National Perinatal Nursing Convention
9. Advanced Radiotherapy Techniques Explored at Educational Events in India
10. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production
11. Health Diagnostic Laboratory, Inc. (HDL, Inc.) Brings Advanced Testing to Capitol Hill, Discusses Health Care Cost Savings and Quality Improvement Potential
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 ... of the "Structural Electronics 2015-2025: Applications, Technologies, ... In-Mold Electronics, Smart Skin, ... Photovoltaics Structural electronics involves electronic ... load-bearing, protective structures, replacing dumb structures such as ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A ... 2016 Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the ... history as home to some of the world’s leading providers of cereal and other ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
Breaking Medicine News(10 mins):